First-in-human dual-epitope nanobody anti-CD5 CAR-T for relapsed/refractory T-ALL/PTCL: Phase I dose-escalation and expansion results from the CONQUER trial.
Year: 2026
Type: conference-abstract
Source: Journal of Clinical Oncology
Institution: Peking University People's Hospital
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7162509753
Cites:
Cited by:
Related to: